Following on from information provided to NICE by the company in September 2018 the appraisal of Renal cell carcinoma - sunitinib [ID1076] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1076

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
21 December 2022 Discontinued. Following on from information provided to NICE by the company in September 2018 the appraisal of Renal cell carcinoma - sunitinib [ID1076] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
13 December 2018 Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of sunitinib for the adjuvant treatment of early renal cell carcinoma. Following on from advice received from the company, please note that NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if and when the situation changes.
03 July 2017 “This appraisal will be rescheduled because the company has let us know that with the currently available data, it is not possible to ascertain the drug’s cost-effectiveness with sufficient certainty. The company is expecting a data update in September of this year. This delay means that this topic will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim funding from the date of marketing authorisation. ‘
11 May 2017 In progress. In progress
05 December 2016 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual